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Abstract
Background: In most countries of sub-Saharan Africa the control of lymphatic filariasis (LF) is based on annual mass drug
administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission. Here we present
the first detailed study on the effect of 3 repeated MDAs with this drug combination, as implemented by the Tanzanian
National Lymphatic Filariasis Elimination Programme (NLFEP).
Methodology/Principal Findings: Infection and transmission was monitored during a five-year period (one pre-intervention
and four post-intervention years) in a highly endemic community (Kirare village) in north-eastern Tanzania. The vectors were
Anopheles gambiae, An. funestus and Cx. quinquefasciatus. After start of intervention, human microfilaraemia initially
decreased rapidly and statistically significant (prevalence by 21.2% and 40.4%, and mean intensity by 48.4% and 73.7%,
compared to pre-treatment values after the first and second MDA, respectively), but thereafter the effect levelled off. The
initial decrease in microfilaraemia led to significant decreases in vector infection and vector infectivity rates and thus to a
considerable reduction in transmission (by 74.3% and 91.3% compared to pre-treatment level after first and second MDA,
respectively). However, the decrease in infection and infectivity rates subsequently also levelled off, and low-level
transmission was still noted after the third MDA. The MDAs had limited effect on circulating filarial antigens and antibody
response to Bm14.
Conclusion/Significance: Critical issues that may potentially explain the observed waning effect of the MDAs in the later
study period include the long intervals between MDAs and a lower than optimal treatment coverage. The findings highlight
the importance of ongoing surveillance for monitoring the progress of LF control programmes, and it calls for more
research into the long-term effect of repeated ivermectin/albendazole MDAs (including the significance of treatment
intervals and compliance), in order to optimize efforts to control LF in sub-Saharan Africa.
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Introduction
Lymphatic filariasis (LF), resulting from infection with the
mosquito borne filarial nematode Wuchereria bancrofti, is a disfiguring
and disabling disease. It is widespread and a major health problem in
many developing countries and it is one of the most prevalent of the
neglected tropical diseases. Recent estimates indicate that more than
1 billion people live in endemic areas and are at risk of infection, and
more than one third of these are in Sub-Saharan Africa [1]. During
the last decade, forces have been united internationally in the fight
against LF through the formation of the Global Programme to
Eliminate LF (GPELF) which provides guidance and support to
national control programmes with an anchorage in the World Health
Organization [2,3].
The principal measure currently recommended for LF control is
annual community-wide mass drug administration (MDA) of two-
drug combinations to identified communities in endemic areas
[2,4–6]. In most endemic countries a combination of diethylcar-
bamazine (DEC) and albendazole is used, but due to the risk of
serious adverse reactions in individuals infected with Onchocerca
volvulus, a combination of ivermectin and albendazole is used in
African countries which are co-endemic for onchocerciasis.
Although the MDAs rarely completely clear the W. bancrofti
infection from the treated individual, it is assumed that the
reduction in the microfilarial load in the endemic population will
lead to a simultaneous reduction – or even elimination – of
transmission. Hence the term ‘‘transmission interruption’’ has
been adopted for this strategy. Monitoring and regular evaluation
www.plosntds.org 1 June 2010 | Volume 4 | Issue 6 | e696of the effect of the control efforts is important in order to be able to
quantify the impact, to make evidence based programme
adjustments, and to eventually make a decision to stop the
activities when the goal has been reached [7,8].
LF is widespread in Tanzania. Particular high endemicity is
seen along the coast of the Indian Ocean and in areas adjacent to
the great lakes. Tanzania was one of the first countries in Africa to
initiate implementation of control, with the Tanzanian National
Lymphatic Filariasis Elimination Programme (NLFEP) being
launched in 2000 [9]. The goal of the NLFEP is to apply annual
MDA with a combination of ivermectin (150–200 mg/kg) and
albendazole (400 mg) to all individuals aged 5 years and above in
selected programme areas. It has previously been shown in
Tanzania that this treatment regimen drastically reduce the W.
bancrofti microfilarial load [10].
Tanga Region, located in the north-eastern part of Tanzania,
was enrolled in the NLFEP and received the first MDA in October
2004. A study to monitor the effect of the programme in a highly
endemic community in this region (Kirare village) was initiated in
October 2003 (one year before the planned start of MDAs) in
order to obtain baseline data on infection and transmission before
start of control activities and to subsequently monitor the effect of
control. Here we report on the effect of the first three rounds of
MDA given by the Tanzanian NLFEP on infection and
transmission of LF in Kirare village. To our knowledge this is
the first detailed assessment of the effect of an ivermectin/
albendazole based MDA programme for LF control in Sub-
Saharan Africa.
Methods
Study design
The main part of the study was conducted in Kirare, a village
located approximately 20 km south of Tanga town (Tanzania)
along the Tanga-Pangani road, in an area known to be highly
endemic for LF [10,11]. Prior to the study there had been no
attempts to control LF in the study site, and antifilarial drugs had
not been available.
The LF endemic districts of Tanga Region were included in the
NLFEP and received the first round of MDA in October 2004. It
was the intention that MDAs should be implemented during every
month of October in subsequent years, but logistic and financial
constraints lead to delays. The next two MDAs took place in
February 2006 and May 2007, while the fourth MDA was
scheduled for November 2008. The present paper reports on the
effect of the first three MDAs, until October 2008.
In order to get a year of baseline information about vectors and
transmission before the first MDA, weekly entomological surveil-
lance covering 50 households was initiated in Kirare in November
2003. This activity has continued uninterrupted since then. A
cross-sectional examination for clinical manifestations related to
LF and for W. bancrofti microfilariae (mf) covering individuals $1
year was carried out during the month prior to the first MDA. It
was attempted to make similar cross-sectional surveys for mf in the
month prior to subsequent MDAs, but due to postponements of
the MDAs, the next mf examinations of the human population
took place in January 2006, January 2007, October 2007 and
October 2008. During the cross-sectional surveys, individuals
living in the households used for mosquito collections were
requested to provide a venous blood sample for serology.
Ethics
Village meetings were held before and regularly during the study
periodinthenational language (Swahili,which iswidely spokenand
understood in the area) to inform the villagers about the study
contents and implications and to obtain their cooperation. The
meetings included information about individuals’ right to withdraw
from participation during any part of the study without negative
consequences. Prior to any blood sampling or clinical examination,
the individual was asked if the purpose and consequences as
explained during the meetings had been understood, and questions
for further clarification were answered. Their oral consent to
participate (from adults, and from parents or guardians of
individuals less than 15 years old) was recorded on the survey
form. Oral consent is the traditional way for making agreements in
the study area, whereas written consent is unfamiliar and would
cause suspicion and refusal to participate. Permission and ethical
clearance to carry out the study (including the use of oral informed
consent) was granted by the Medical Research Coordinating
Committee of the National Institute for Medical Research (NIMR)
in Tanzania and the study protocol was reviewed by the Danish
National Committee on Biomedical Research Ethics.
Entomological surveillance
The village houses were mapped and the name, age and sex of
villagers were registered. The households were divided into 50
groups of nearly equal size and one household from each group was
randomlyselectedfor surveillance ofvectorsand transmission.Ifthe
selected household had only one inhabitant it was de-selected, and
the nearest household to it that held at least two inhabitants was
selected instead. From the beginning of November 2003, mosqui-
toes were collected from each of the selected households once
weekly (10 houses were sampled on the night of each weekday) as
described previously [12]. Briefly, on the night of collection, a
battery-operated CDC light trap was placed beside an occupied bed
provided with an un-impregnated mosquito net. The traps were
turned on at 18.00 hours and off at 06.00 hours. Mosquitoes were
collected from the traps in the morning and brought to the
laboratory in Tanga. They were knocked down with chloroform,
Author Summary
Lymphatic filariasis (LF) is a disabling mosquito borne
parasitic disease and one of the major neglected tropical
diseases. In most countries of Sub-Saharan Africa the
control of LF is based on yearly mass drug administration
(MDA) with a combination of ivermectin and albendazole,
in order to interrupt transmission. We monitored the effect
of 3 repeated MDAs with this drug combination, as
implemented by the Tanzanian National Lymphatic
Filariasis Elimination Programme, on human infection
and mosquito transmission during a five-year period (one
pre-intervention and four post-intervention years) in a
highly endemic community in north-eastern Tanzania.
After start of intervention, human infection with the blood-
stage larva of the parasite (microfilaria) initially decreased
rapidly, leading to considerable reduction in transmission.
The effects thereafter levelled off and transmission still
occurred at low level after the third MDA. The MDAs had
limited effect on molecular markers of adult worm burden
(circulating filarial antigens) and transmission exposure
(antibodies to Bm14 antigen) in the human population.
The study highlights the importance of monitoring and
regular evaluation in order to make evidence based
programme adjustments, and it points to a need for
further assessment of the long-term effect of repeated
ivermectin/albendazole MDAs (including the importance
of application intervals and treatment coverage), in order
to optimize efforts to control LF in sub-Saharan Africa.
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mosquitoes were dissected and examined for the first-stage,
second-stage and human infective third-stage larvae of W. bancrofti.
To cross-check the results of the initial infection examinations, all
larvae-positive slides and 20% of the negative slides were stained in
Mayer’s acid haemalum and later re-examined.
Examination of the human population
Examinations were carried out during the evening. Clinical
examination by an experienced clinician started at 20.00 hours.
Signs of chronic LF were graded as described [13], but in this
presentation lymphedema/elephantiasis $ grade I (loss of contour,
pitting edema) and hydrocele $ grade II (true hydrocele $6c m ,
with fluid accumulation) are reported as elephantiasis and hydrocele,
respectively. Blood sampling for quantification of mf started at 21.00
hours. From each individual, 100 mlo ff i n g e rp r i c kb l o o dw a s
collected in a heparinised capillary tube and transferred to a tube
with 900 ml of 3% acetic acid. Later in the laboratory, the specimens
were transferred to a counting chamber and examined for mf under
a compound microscope [14]. All specimens were blindly examined
twice by two different technicians, and the mean count was recorded
as the mf intensity.
Additional venous blood samples of 5 ml were collected from
volunteers from the 50 mosquito collection houses immediately
after the finger prick blood sampling. Specimens were collected in
plain vacutainer tubes, which were left overnight at 4uC for the
blood to clot. Serum was collected the following day and stored
at 220uC until use.
Assessment of treatment coverage and bed net use
The treatment coverage was assessed in two different ways.
First, the official programme coverage for Kirare Ward (which in
addition to Kirare also includes another slightly larger neighbour-
ing village) was obtained from the regional NLFEP office in Tanga
(‘reported coverage’). This had been calculated as the recorded
number of treatments given in the ward by the programme
divided by the registered population $5 years for the ward.
Second, the study conducted a questionnaire survey in the village
within one month after each MDA, during which individuals $5
years were asked whether or not they had taken the treatment
(‘surveyed coverage’).
At the time of the start of the study in 2003, very few houses in
Kirare possessed a bed net. However, it was observed that bed nets
gradually became more common, and a questionnaire survey
carried out in June 2007 (together with the survey for MDA
coverage) indicated that the number of bed nets available in the
households of Kirare relative to the number of study individuals
amounted to 18.6%.
Tests for circulating filarial antigens and antibodies to
Bm14
Serum samples were examined in the laboratory in Denmark.
Before handling and testing of sera, 3 ml/ml TNBP (tri-n-butyl-
phosphate, Sigma T-4908) and 10 ml/ml Tween 80 (polyoxyethy-
lenesorbitan, Sigma P-1754) were added to the specimens to
inactivate lipid coated vira [15].
The specimens were examined for specific circulating filarial
antigen (CFA) by using the TropBio enzyme linked immunosor-
bent assay (ELISA) kit for serum specimens (catalog no. 03-010-01;
TropBio Ltd., Pty., Townsville, Australia). The test was performed
according to procedures from the manufacturer. Serum specimens
with a response $ that of the enclosed standard 2 (32 CFA units)
were considered positive for CFA.
The specimens were moreover examined by ELISA for IgG4
antibodies to the recombinant antigen Bm14, supplied by the NIH/
NIAID Filariasis Research Repository Center (FR3; Smith College,
Massachusetts, USA). The ELISA was performed according to
procedure enclosed with the supplied antigen. All incubations were
carried out at room temperature on a shaker. Briefly, ELISA plates
(Maxisorp F96 immunoplates, Nunc, Denmark) were coated over-
night with 100 mld i l u t e da n t i g e n( 2mg Bm14 per ml in carbonate
buffer, pH 9.6). The plates were then washed 3 times with PBS/0.5%
Tween 20, blocked by adding 200 ml/well of the same buffer
containing 5% heat inactivated foetal calf serum (FCS) for 30
minutes, and washed 3 times. Plates were thereafter incubated for 1
hour with 100 ml of the human test serum diluted 1:500 with PBS/
Tween/FCS, washed 3 times with PBS/Tween, incubated for 1 hour
with 100 ml horse-radish peroxidase-labelled mouse-anti-human
IgG4 (M1331, Sanquin, Amsterdam, Netherlands) diluted 1:2000
with PBS/Tween/FCS, and washed 3 times with PBS/Tween.
Finally, 100 ml OPD substrate solution, prepared from OPD tablets
as instructed by the manufacturer (Dako, Denmark) was added to
each well, the plate was incubated for 10 minutes in the dark, and the
optic density (OD value) was read at 490 nm on an ELISA reader
(Microplate reader 550, Bio-Rad, USA). Serum specimens with an
OD-value higher than the mean plus four standard deviations of OD-
values for five control individuals from a non-endemic area
(Denmark) were considered positive for IgG4 to Bm14.
In all ELISAs (for CFA and IgG4) specimens were tested in
duplicate (arithmetic mean of the two tests was used as the result),
and all sera from the same person were tested on the same ELISA
plate.
Data analysis
The mf intensities were adjusted for sampling time by multi-
plying the counts with a time-specific factor. A list of the
adjustment factors for every 10 minutes between 20.00 and
02.00 hours, and the method for deriving these on the basis of a
detailed analysis of the mf periodicity curve, were presented
previously [16]. Geometric mean intensities (GMIs) of microfilar-
aemia, CFA intensity and Bm14 antibody level were calculated as
antilog ((g log x+1)/n)21, with x being the mf/ml, CFA units
or OD-values, respectively, and n the number of individuals
included.
Only individuals registered as inhabitants in Kirare during the
pre-MDA survey were included in the post-MDA follow-up
surveys (i.e. newborn or immigrants were not included).
The entomological indices for vector biting and transmission were
calculated as previously[12]. Briefly, the monthlybiting rate (MBR; a
measure of the number of mosquito bites per person in the month)
was calculated as: (total mosquito catch 6 days in month 63)/
(numberofcatchingnights6numberoflighttraps62). The monthly
transmission potential (MTP; a measure of the number of infective
larvae to which a person is exposed in the month) was calculated as:
(MBR 6 total number of infective larvae seen in the dissections)/
(number of mosquitoes dissected). The ‘infectivity rate’ was calculated
as the percent of mosquitoes infected with infective larvae (L3) and
the ‘infection rate’ as the percent of mosquitoes infected with any
stage of the parasite (L1, L2 and/or L3).
Results
Lymphatic filariasis in the community before treatment
During the baseline surveys in September 2004, a total of 1,112
individuals aged 1 year and above were registered in Kirare
(Table 1). Among these, the male to female ratio was 0.96 and
51.7% were less than 20 years old.
MDA for Filariasis in Tanzania
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for mf, and 225 (24.5%) were mf positive (Table 1). The
prevalence increased rapidly by age in the younger age groups,
until a level was reached during late teenage years. It was
significantly higher among males than among females (27.7% vs.
21.7%; chi-square test, P,0.05), and this trend was seen for all
age groups. The mf intensities among mf-positive individuals
ranged from 10 to 25,370 mf/ml blood. The overall mf GMIs
were 4.11 mf/ml when calculated for all examined individuals
and 781.3 mf/ml when calculated for mf positive individuals only
(Table 1). These indices were also significantly higher for males
than for females (6.10 vs. 2.82 and 1192.4 vs. 486.1; t-test,
P=0.002 and P,0.001, respectively). Chronic manifestations of
filariasis were common in Kirare. Thus, 4.1% of the examined
adults ($20 years old) had elephantiasis of the leg, and 32.8% of
adult males had hydrocele.
Dissection of the mosquitoes caught from the 50 collection
houses during the 11 months pre-MDA period indicated that
An. funestus, An. gambiae and Cx. quinquefasciatus were vectors of
W. bancrofti (Table 2). Among these, An. funestus was the most
abundant (mean MBR of 71.3), had the highest W. bancrofti
infection prevalence (infectivity rate of 2.3%; infection rate of
4.5%) and contributed most to transmission (mean MTP of
3.5), followed by An. gambiae (49.3, 1.4%, 3.8% and 1.9,
respectively) and Cx. quinquefasciatus (53.6, 0.5%, 2.0% and
0.7, respectively). Overall, the two Anopheline vectors were
responsible for 88.5% of the transmission during the pre-MDA
period. Vector biting and parasite transmission varied by
season (Figure 1), but was generally most intense during and
shortly after the rainy seasons (months of November/December
and March/April/May).
MDA treatment coverage
Treatment coverage during the three MDAs, as assessed
separately by the NLFEP (‘reported coverage’) and the study
(‘surveyed coverage’), are shown in Table 3. The results from the
two assessment methods differed considerably. This was most
marked for the first MDA in October 2004 during which surveyed
coverage was higher (82.3%) than reported coverage (62.1%). For
the next two MDAs in February 2006 and May 2007, reported
coverages were higher than surveyed coverages (94.8% vs. 79.0%
and 80.0% vs. 69.9%, respectively).
Effect of MDAs on microfilaraemia
The effect of the MDAs on microfilaraemia is shown in Table 4
and Figure 2. Although the survey coverage decreased from one
survey to the next, the mean age remained stable (range of means
(6 standard deviation): 24.3620.2 to 25.4620.8). Following each
MDA the mf prevalence decreased progressively, from 24.5% in
the pre-MDA survey (September 2004) to 10.1% five months
after the third MDA (October 2007). Statistical analysis of data
from individuals examined at both time points indicated
significant decreases in mf prevalence from surveys 1 to 2, 2 to
3 and 3 to 4, but not from survey 3 to 5 (n=709, 655, 606 and
491; McNemar’s chi-square test for paired proportions, P,0.001,
P,0.001, P=0.002 and P=0.14, respectively). During the one-
year period without treatment, from October 2007 to October
2008, there was a trend towards an increase in prevalence from
10.1 to 10.6%, but the difference was not statistically significant
(n=458; P=0.20).
A similar trend was seen for the mf GMIs calculated on the basis
of all examined individuals, but the reductions observed during the
first three periods were proportionately greater than the reductions
seen for the prevalences (reached 17.0% of pre-MDA values in
October 2007). Statistical analysis of data from individuals
examined at both time points again indicated significant decreases
from surveys 1 to 2, 2 to 3 and 3 to 4, but not from survey 3 to 5
(paired t-test, P,0.001, P,0.001, P=0.007 and P=0.30,
respectively). Also, a small but statistically insignificant increase
was seen in this parameter between October 2007 and October
2008 (paired t-test, P=0.11).
The mf GMI among the mf positives decreased even more
steeply during the first two periods (reaching 19.3% of pre-
MDA values in January 2007). It thereafter increased to 24.4%
and 29.9% of pre-MDA values in October 2007 and October
2008, respectively. However, in analyses of data from indivi-
duals who were positive during both examinations the increases
did not reach statistical significance, neither between January
and October 2007, nor between January 2007 and October
2008 (n=43 and 40; Paired t-test, P=0.40 and 0.19,
respectively).
Effect of MDAs on vectors and transmission
The vector species composition and vector density changed
considerably from the pre-MDA to the three post-MDA periods
Table 1. Wuchereria bancrofti microfilaraemia in Kirare village as seen during the pre-MDA survey in September 2004.
Age group
in years
No.
registered
No. examined
for mf (%*)
No. positive
for mf (%**)
Mf GMI among all
examined
#
Mf GMI among
positive
#
1–4 134 116 (86.6) 1 (0.9) 0.04 70.0
5–9 190 165 (86.8) 22 (13.3) 1.30 721.2
10–14 177 154 (87.0) 43 (27.9) 5.68 896.0
15–19 74 52 (70.3) 15 (28.8) 5.78 760.9
20–29 148 111 (75.0) 42 (37.8) 10.49 634.0
30–39 137 115 (83.9) 37 (32.2) 7.12 670.3
40–49 89 74 (83.1) 21 (28.4) 5.78 849.6
50+ 163 132 (81.0) 44 (33.3) 9.60 1190.0
Total 1112 919 (82.6) 225 (24.5) 4.11 781.3
*) of registered.
**) of examined.
#) In mf/ml blood.
doi:10.1371/journal.pntd.0000696.t001
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pre-MDA period, with An. gambiae and An. funestus comprising
68.5% of the catch, while Cx. quinquefasciatus predominated and
comprised 84.1% of the catch during the three post-MDA periods
combined (chi-square test, P,0.001). The overall mean MBR was
reduced from 174.3 during the pre-MDA period to 119.8 during
the three post-MDA periods. As discussed later, these changes
between pre- and post-MDA periods were probably not related to
the MDAs.
For the vector species combined, the start of MDA led to a
significant decrease in the vector infectivity rate, from 1.43% of
vectors containing infective larvae in the pre-MDA period to 0.45%
and 0.17% in the first and second post-MDA periods, respectively
(chi-square test, P,0.001 and P=0.004, respectively). In the third
post-MDA period, this trend continued (to 0.11%) but the decrease
was statistically insignificant (chi-square test, P=0.42). Similar trends
of decrease in infectivity rate were seen for the individual vector
species (Table 2). These decreases resulted in a considerable and
progressive reduction in transmission of W. bancrofti infective larvae.
Thus, the overall mean MTP reduced from 6.08 during the pre-
MDA period to 1.56, 0.53 and 0.22 (25.7%, 8.7% and 3.6% of pre-
MDA values) during the first, second and third post-MDA periods,
respectively (Figure 3B). Transmission by the two Anopheline
vectors was reduced to an even greater extent, and was almost
undetectable during post-MDA periods 2 and 3. For Cx.
quinquefasciatus, however, the rise in MBR after start of treatment
led to an initial rise in transmission during the first post-MDA
period, which was then followed by a reduction in subsequent
periods. Overall, Cx. quinquefasciatus was responsible for most
transmission after start of treatment (contributed 82.1% of the
MTP during the three post-MDA periods combined).
For the vector species combined, the first and second rounds of
MDA both led to significant decreases in vector infection rates (i.e.
percent of vectors infected with any stage of the parasite), from
3.5% in the pre-MDA period to 1.6% and 0.31% in the first and
second post-MDA periods (chi-square test, P,0.001 for both tests).
However, this was followed by a significant increase to 0.79% in
the third post-MDA period (chi-square test, P,0.001). Similar
patterns were seen for the individual vector species (Figure 3C).
Effect of MDAs on CFA and antibodies to Bm14
Ninety individuals from the mosquito collection houses
volunteered to provide a serum specimen at the pre-MDA survey,
and these were requested to also provide a specimen at the four
post-MDA surveys. All specimens were analysed for CFA and
IgG4 antibodies to Bm14 (Table 5). There were only limited
changes in prevalence of CFA and Bm14 antibody positivity
between the pre-MDA and the fourth post-MDA survey. When
data from individuals examined at both time points were analysed
statistically, a significant difference between pre-MDA and
Figure 1. Seasonal variation in monthly biting rate (MBR) and monthly transmission potential (MTP) in Kirare village during the
study period (November 2003 to October 2008). MBR, panel A; MTP, panel B. Thick black line = all vector species combined; Thin green line =
Anopheles gambiae; Thin red line = An. funestus; Thin blue line = Culex quinquefasciatus. Arrows indicate rounds of mass drug administration.
doi:10.1371/journal.pntd.0000696.g001
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decrease in CFA prevalence in October 2008 (n=49; McNemar’s
test, P=0.03).
More pronounced decreases were seen in the mean levels of these
indices with increasing numbers of MDAs. Thus, the CFA GMI
among all examined individuals decreased to 44.2% of pre-MDA
level (from 106.9 to 47.3 CFA units) and the Bm14 antibody OD-
value among all examined decreased to 51.5% of pre-MDA level
(from to 0.784 to 0.405) between the pre-MDA survey and the
fourth post-MDA survey. When data from individuals examined at
both time points were analysed statistically, all four post-MDA CFA
GMIs were significantly lower than the pre-MDA value (n=66, 72,
61 and 49; Paired t-test, P=0.03, ,0.001, ,0.001 and ,0.001,
respectively), and all four post-MDA Bm14 OD-values were
significantly lower than the pre-MDA value (paired t-test, P,
0.001 for all tests).
Discussion
Annual MDA with a combination of ivermectin and albenda-
zole is recommended for the control of LF in African countries
which are co-endemic for onchocerciasis [2,4,6]. Early trials in
selected mf positive individuals [17–19] as well as community
based field trials [10,20–22] demonstrated that this drug
combination safely and effectively reduced W. bancrofti microfilar-
aemias, thus making it suitable for use in large scale transmission
control [23]. Here we report on the effect of repeated MDAs with
this drug combination in a highly LF endemic community of
Tanzania, as applied by the NLFEP.
Table 2. Vector mosquito catches from the 50 collection houses in Kirare village, and the results of dissections, during the pre-
MDA period and the three post-MDA periods.
Total An. gambiae An. funestus Cx. quinquefasciatus
Pre-MDA period (11 months)*
No. mosquitoes caught 8346 2335 3385 2626
No. mosquitoes dissected 5396 1477 2080 1839
No. with infection (% of dissected) 187 (3.5) 56 (3.8) 94 (4.5) 37 (2.0)
No. with L3 (% of dissected) 77 (1.4) 20 (1.4) 48 (2.3) 9 (0.5)
No. of L3 153 51 87 15
Post-MDA period 1 (16 months)**
No. mosquitoes caught 8872 527 929 7416
No. mosquitoes dissected 7840 338 705 6797
No. with infection (% of dissected) 128 (1.6) 7 (2.1) 20 (2.8) 101 (1.5)
No. with L3 (% of dissected) 35 (0.4) 1 (0.3) 6 (0.9) 28 (0.4)
No. of L3 101 1 15 85
Post-MDA period 2 (15 months)***
No. mosquitoes caught 7849 970 75 6804
No. mosquitoes dissected 7071 790 67 6214
No. with infection (% of dissected) 22 (0.3) 3 (0.4) 0 (0.0) 19 (0.3)
No. with L3 (% of dissected) 12 (0.2) 1 (0.1) 0 (0.0) 11 (0.2)
No. of L3 34 3 0 31
Post-MDA period 3 (18 months)****
No. mosquitoes caught 9892 631 1148 8113
No. mosquitoes dissected 9088 564 848 7676
No. with infection (% of dissected) 72 (0.8) 7 (1.2) 4 (0.5) 61 (0.8)
No. with L3 (% of dissected) 10 (0.1) 1 (0.2) 1 (0.1) 8 (0.1)
No. of L3 17 1 1 15
*Nov-03 to Sep-04;
**Oct-04 to Jan-06;
***Feb-06 to Apr-07;
****May-07 to Oct-08.
doi:10.1371/journal.pntd.0000696.t002
Table 3. Treatment coverage during mass drug
administration (MDA) 1, 2 and 3.
MDA no. Time of MDA Treatment coverage in %
Reported
coverage*
Surveyed
coverage**
1 Oct-04 62.1 82.3
2 Feb-06 94.8 79.0
3 May-07 80.0 69.9
*) Official NLFEP coverage for eligible individuals in Kirare Ward (include Kirare
village plus one neighboring village of slightly larger size).
**) Interview of individuals $5 years (at time of MDA) carried out within one
month after treatment. 99.7%, 100.0% and 81.0% of these were interviewed
during MDA 1, 2 and 3, respectively.
doi:10.1371/journal.pntd.0000696.t003
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intervention started, in terms of infection, disease and transmis-
sion. Thus, the overall prevalence among those examined was
24.5% for mf, 53.3% for CFA, and 78.9% for antibodies to Bm14.
Four percent of the adults moreover suffered from limb
elephantiasis, while 32.8% of adult males had hydrocele. The
vectors were identified as An. gambiae, An. funestus and Cx.
quinquefasciatus, and the two Anopheles species were responsible for
most of the transmission during the baseline year. The general
pattern of LF in the study community thus resembled that
previously reported from the same area [11–13,24]. However, in
contrast to experience from the earlier studies, the survey team
faced reluctance from some of the villagers to participate in the
cross-sectional examinations. This behaviour appeared to be
related to ‘disturbances’ created by the location of the village along
the main road between Tanga and Pangani and to a strong
engagement of some of the villagers in local politics. Despite great
efforts made, the survey coverage for blood sampling decreased
from one survey to the next.
The weekly collection of vectors from the 50 selected house-
holds posed less of a challenge, as the inhabitants were generally
pleased to see mosquitoes being caught and removed from their
houses. The collection and dissection of vectors is a time-
consuming and expensive task, which is not recommended as a
routine for monitoring LF elimination programmes. However, it
provides the most exact information about vector dynamics and
transmission of LF, and as such is an important research tool in
projects aiming to investigate the effect of control programmes in
detail. A newly developed PCR technique, capable of distinguish-
ing the different parasite stages in the vectors, may replace the
laborious dissection activity in future assessments of LF transmis-
sion [25].
According to the original plan from 2004, the NLFEP should
implement a MDA each year in October. However, due to the
complicated logistics and limited funds available the programme
(which includes a large part of the country) faced delays in
activities. As a result, the three inter-MDA periods covered by the
present study widened from 12 to 16, 15 and 18 months,
respectively. Due to uncertainty of the timing of the MDAs, the
time-interval between the cross-sectional surveys in Kirare and the
MDAs moreover often became considerably longer than desired.
The treatment coverage is a key factor to consider when
assessing the impact of MDAs [7,26,27]. However, exact
information on treatment coverage is generally not easily available
from large scale control programmes, and the reliability of the data
may be highly variable, as personal and political interests and
Figure 2. The effect of three rounds of mass drug administration (MDA) on Wuchereria bancrofti microfilaemia in Kirare village. Lines
indicate microfilaria (mf) prevalence (N), mf geometric mean intensity (GMI) among all examined individuals (&) and mf GMI among positive
individuals only (m). All indices are expressed in % of the baseline value. Vertical stippled lines indicate rounds of MDA.
doi:10.1371/journal.pntd.0000696.g002
Table 4. Microfilaraemia in Kirare village during the pre-MDA survey (September 2004) and the four post-MDA surveys (January
2006, January 2007, October 2007 and October 2008).
Survey no. Time of survey No. examined (%) No. positive for mf (%) Mf GMI for all examined* Mf GMI for positives*
1 Sep-04 919 (82.6) 225 (24.5) 4.11 781.3
2 Jan-06 798 (71.8) 154 (19.3) 2.12 360.4
3 Jan-07 831 (74.7) 121 (14.6) 1.08 150.7
4 Oct-07 674 (60.6) 68 (10.1) 0.70 190.8
5 Oct-08 565 (50.8) 60 (10.6) 0.75 194.7
The target population for all surveys was the 1112 individuals aged $1 year in at the pre-MDA survey.
*) In mf/ml blood.
doi:10.1371/journal.pntd.0000696.t004
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quality. Two different approaches were used to gather information
about treatment coverage in the present study. First, the official
‘reported coverage’ was obtained from the NLFEP office in Tanga
Region. This is calculated on the basis of the drug distributors’
recordings during drug delivery, and may to some extent be
affected by the time pressure during drug distribution and the
attention and honesty of the distributors. The ‘reported coverage’
moreover depends on the quality of the population data used as
the denominator in the calculations. Second, a ‘surveyed coverage’
was obtained by the study by interviewing villagers individually
after the MDA. The quality of this figure may be affected by
memory and honesty of those interviewed. Some villagers may feel
ashamed admitting that they did not take the drugs, when health
messages have encouraged them to do so. This latter issue may
have had the highest impact during the first MDA, when the
overall concept of MDAs was new and information dissemination
most intensive, and may perhaps have accounted for the large
difference in treatment coverage obtained with the two approaches
in 2004. Both approaches indicated a decrease in treatment
coverage from the second to the third MDA, thus stressing the
importance of continued dissemination of health messages
encouraging individuals to participate in the MDAs [28].
The first two MDAs had a considerable and statistically
significant suppressing effect on microfilaraemia in the popula-
tion. Thus, at the January 2007 survey (28 months after first and
12 months after second MDA), the prevalence was reduced by
40.4%, and mf GMI for all examined was reduced by 73.7%,
when compared to pre-MDA values. Following the third MDA, a
further but slightly less significant reduction was seen in these
parameters in October 2007 (reductions by 58.8% and 83.0%,
respectively, compared to pre-MDA). During the last survey in
October 2008 there was no further decrease compared to the
previous survey, but rather a small but statistically insignificant
increase. It may be argued that data from October 2007 were
collected only 5 months after the third MDA, and that
microfilaraemias could therefore be at particularly low levels
due to the short time after treatment. However, even the
apparent decrease in mf prevalence and mf GMI among all
examined between January 2007 and October 2008 was not
statistically significant. The mf GMI among mf positives showed a
trend towards a increase between January 2007 and October
2008 (although still not statistically significant), suggesting that the
apparent waning effect of the MDAs was most marked among
individuals who had not yet cleared their mf (these individuals
also had a considerable higher mean mf burden at pre-MDA
than the other mf positive individuals; results not shown). Possible
reasons for the levelling out of the effect of MDAs on
microfilaraemia in the latter part of the study will be discussed
later.
There was a clear shift in vector species composition between
the pre-MDA period and the period following start of MDA, from
predominantly Anopheles transmission to transmission by Cx.
quinquefasciatus. An earlier study (1998–2001) carried out in a
nearby village (Masaika) had also incriminated Anopheles sp. as the
predominant vectors in the area [12,29]. It is unlikely that the shift
was related to the MDAs. The more frequent use of bed nets by
the village habitants may have contributed to the shift, but bed net
coverage was still rather low in 2008 and cannot have been a
major reason. Rather it could be due to environmental and/or
climatic changes. Examination of the monthly rainfall pattern for
the area (results not shown) did not immediately reveal any obvious
change during the study period, and a more detailed analysis of
environmental factors (including rainfall intensity and frequency
pattern, temperature variations and vegetation cover) that could be
the cause of the observed change in vector populations should be
carried out. It is interesting to note that a significant reduction in
prevalence of malaria cases (malaria and LF share the same
Anopheles vectors) has also been observed in coastal East Africa
during the same period [30]. The observed shift in LF vector
species composition also points to the importance of considering
the complexity of transmission in areas with several vectors. When
conditions for one vector species get worse, other vector species
may thrive and take over the major part of transmission.
The MDA-induced reduction in human microfilaraemia led to
a considerable decrease in transmission, which was obvious for all
three vector species. However, whereas Anopheles transmission was
almost interrupted after the second MDA, that by Cx. quinque-
Figure 3. Mean monthly biting rate. (MBR; A), mean monthly
transmission potential (MTP; B) and vector infection rate (C) in Kirare
village during the pre-MDA period and the three post-MDA periods.
doi:10.1371/journal.pntd.0000696.g003
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supported by the persisting low level of human microfilaraemia
and the large number of vectors. Transmission intensity varied
with the season, and during the latter period of the study almost
exclusively took place during and shortly after the rainy seasons
when vectors were most abundant.
The impact of the MDAs on CFA (an indirect measure of adult
worm burden; [31]) and antibodies to Bm14 (an indirect measure
of infection and/or exposure to transmission; [31]) was limited,
and not nearly as marked as seen in programmes using the
combination of diethylcarbamazine (DEC) and albendazole for
control of LF [31,32]. Thus, although the mean intensity of both
indices had decreased to about half of the pre-MDA level at the
end of the study in October 2008, there was no clear effect on the
prevalences. Previous studies have similarly indicated a limited
effect of the ivermectin/albendazole combination on circulating
filarial antigenemia [10,21], in agreement with the general
understanding that ivermectin is mainly a microfilaricidal drug.
The limited reduction in level of antibodies to Bm14 concurs with
the observed remaining infection burden and continued transmis-
sion of LF in the study community.
The effect of the ivermectin/albendazole MDAs in this study
obviously did not match the reductions in infection and
transmission seen following MDAs with the DEC/albendazole
combination [31–33]. Although the MDAs caused reduction in
microfilaraemia and transmission in relation to pre-MDA levels,
especially after the first two rounds, the waning effect of the MDAs
observed later is a course for concern. There may be a number of
reasons, which needs to be further investigated. First, the intervals
between treatments were longer than the recommended one year
period. An increase in both mf and CFA prevalence was recently
reported after a single MDA with DEC/albendazole had been
missed in Haiti [34]. As ivermectin does not kill the adult worms,
new mf may start to appear soon after drug action cease. Previous
studies showed that the ivermectin/albendazole combination had
maximum effect on the microfilaraemia at 3–6 months after
treatment [10,20]. MDAs might therefore have to be implemented
even more frequently than once yearly with this drug combination
to achieve a continued long-term reduction in mf burden. Second,
the treatment coverage obtained (whether ‘reported’ or ‘surveyed’)
may, as argued earlier, not be a reliable measure of the proportion
of individuals actually swallowing the drugs, and the ‘true’
coverage could be lower than indicated. There is a great need
both for development of improved ways of assessing the ’true’
treatment coverage in MDAs and for development of better means
to increase this coverage [28,35]. Third, knowledge on the long-
term effect of repeated treatment with the ivermectin/albendazole
combination is limited. A study in Ghana showed a similar effect
during first and second treatment (given to the same individuals
with a one year interval), but it cannot be excluded that the effect
may wane with the increasing number of MDAs [22].
The present study emphasizes the importance of ongoing
surveillance for monitoring the progress of LF control pro-
grammes, in order to optimize control efforts in Sub-Saharan
Africa. It calls for more research into the long-term effect of
repeated ivermectin/albendazole MDAs (including the signifi-
cance of treatment intervals and compliance), and it suggests that
evidence based programme adjustments, perhaps combined with
introduction of additional measures such as vector control [6,36]
will be necessary in order to reach the goal of LF elimination
within a reasonable time-frame.
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Table 5. Circulating filarial antigen (CFA) and antibody to Bm14 in 90 volunteers from the mosquito collection houses in Kirare
village.
Survey no.
Time of
survey
No.
examined CFA Antibody to Bm14
No. positive (%)
GMI for all
examined*
GMI for
positives* No. Positive (%)
GMI for all
examined**
GMI for
positives**
1 Sep-04 90 48 (53.3) 106.9 4835 71 (78.9) 0.784 1.083
2 Jan-06 66 35 (53.0) 96.1 3106 53 (80.3) 0.642 0.854
3 Jan-07 72 37 (51.4) 79.2 2871 56 (77.8) 0.452 0.614
4 Oct-07 61 32 (52.5) 81.9 2386 48 (78.7) 0.467 0.627
5 Oct-08 49 22 (44.9) 47.3 2369 37 (75.5) 0.405 0.568
The individuals provided a serum specimen at the pre-MDA survey (September 2004)
# and were followed up at the four post-MDA surveys (January 2006, January 2007,
October 2007 and October 2008).
#) 55 females and 35 males; Age in 2004: 1–66 years (mean 24.1 years).
*) In CFA units.
**) In OD-values.
doi:10.1371/journal.pntd.0000696.t005
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